Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSONANCE French Extension: Long-term Ocrelizumab in Progressive Multiple Sclerosis
2024-516433-13-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Centre Hospitalier Universitaire de Nice. Planned start Sep 2024; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-516433-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516433-13-00.